Dr. Igor Barjaktarevic, MD, MS

Dr. Barjaktarevic practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Barjaktarevic's NPI, 1932345105, was assigned on December 18, 2008. Dr. Barjaktarevic graduated from University of Belgrade Faculty of Medicine in 2002. Dr. Barjaktarevic's California license number on file is A121964.

Dr. Barjaktarevic's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Barjaktarevic's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. Dr. Barjaktarevic is also affiliated with UCLA Santa Monica Medical Center. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Barjaktarevic to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barjaktarevic practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Barjaktarevic's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Barjaktarevic is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Barjaktarevic's licenses on file in 2 states: California and New York.

Dmand AI lists asthma, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pulmonary fibrosis and tobacco use among the conditions Dr. Barjaktarevic treats.

CMS data shows 573 Medicare services from Dr. Barjaktarevic across 8 procedure codes in 2024, for 120 Medicare patients. Medicare paid $81,950 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 120 Medicare patients who saw Dr. Barjaktarevic in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 50% are also on Medicaid. Their average risk score is 3.49, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Barjaktarevic's median patient age at 59, with 44% women.

In 2024, Dr. Barjaktarevic wrote 300 Medicare Part D claims for 54 patients. 43% of them were for generic drugs. CMS names the drug for 150 of them, across 6 drugs with 11 or more claims each, at $66,720 in total drug cost. In 2023, CMS named 239 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Barjaktarevic for performance year 2024, reported as part of a group. Dr. Barjaktarevic accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Barjaktarevic as offering telehealth.

Dmand AI links 41 papers to Dr. Barjaktarevic, published from 2013 to 2025. 2018 was the busiest year, with 6. The most frequent topics are Pulmonary Disease, Chronic Obstructive, Forced Expiratory Volume and Lung. Dr. Barjaktarevic has published most often in Chronic Obstr Pulm Dis. Dr. Barjaktarevic's most frequent co-authors are Meilan King Han, MD, Jeffrey Louis Curtis, MD and Stephen Paul Peters, MD.

CMS Open Payments shows 421 general payments to Dr. Barjaktarevic from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. AstraZeneca Pharmaceuticals LP paid the most, $100,751. It also lists 1 research payment totaling $250 in 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Barjaktarevic, most recently CMS Stage 1 EHR in 2013.

Dr. Barjaktarevic graduated from University of Belgrade Faculty of Medicine in 2002.

Dr. Barjaktarevic is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.